FDA Approves New Dosage of Copaxone for MS

Article

The FDA approved a new dosage of Copaxone that allows patients with relapsing-remitting multiple sclerosis to take the drug three times a week instead of daily.

The FDA approved a new dosage of Copaxone (glatiramer acetate injection), 40 mg/mL subcutaneous injection, that allows patients with relapsing-remitting multiple sclerosis (MS) to take the drug three times a week instead of daily—reducing the number of required injections by 60%. The 20-mg dose of Teva’s Copaxone remains available.

Data from the Phase II GALA study of more than 1,400 MS patients showed that the new three-times-weekly administration of Copaxone significantly reduced relapse rate at 12 months. The new formulation also showed a favorable safety and tolerability profile.

As patients transition to the new three-times-weekly Copaxone formulation from the daily-use version, Teva’s Shared Solutions patient support center is ready to assist them and their healthcare providers at (800) 887-8100.

The most common side effects of Copaxone are redness, pain, swelling, itching or a lump at the site of injection, flushing, rash, shortness of breath, and chest pain. For additional prescribing instructions and precautions, consult product labeling at www.copaxoneprescribinginformation.com.

Recent Videos
How to Adequately Screen for and Treat Cognitive Decline in Primary Care
James R. Kilgore, DMSc, PhD, PA-C: Cognitive Decline Diagnostics
Stephanie Nahas, MD, MSEd | Credit: Jefferson Health
John Harsh, PhD: Exploring Once-Nightly Sodium Oxybate Therapy for Narcolepsy
John Harsh, PhD
© 2024 MJH Life Sciences

All rights reserved.